News
MYGN
18.30
+1.78%
0.32
Weekly Report: what happened at MYGN last week (0415-0419)?
Weekly Report · 4d ago
MYRIAD GENETICS INC <MYGN.O>: BOFA GLOBAL RESEARCH CUTS PRICE OBJECTIVE TO $18 FROM $22
Reuters · 04/17 10:25
MYRIAD GENETICS INC <MYGN.O>: TD COWEN CUTS TARGET PRICE TO $23 FROM $26
Reuters · 04/17 10:02
BUZZ-U.S. STOCKS ON THE MOVE-WiSA Technologies, Rivian Automotive, Cigna Group
The Nasdaq and the S&P 500 were muted on Tuesday as higher Treasury yields pressured equities. The blue-chip Dow bucked the trend on robust results from health insurance heavyweight UnitedHealth. The Dow Jones Industrial Average was up 0.13% at 37,783.35. UnitedHealth Group's quarterly results beat expectations.
Reuters · 04/16 17:52
BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Intra-Cellular Therapies, China SXT Pharmaceuticals
Dow Jones Industrial Average up 0.13% after upbeat results from health insurer UnitedHealth. Morgan Stanley, Intra-Cellular Therapies, China SXT Pharmaceuticals among top stocks on the move. Higher Treasury yields and conflict in the Middle East keep investors on edge.
Reuters · 04/16 15:39
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
Study shows exceptional positive predictive value for 22q11.2 microdeletion screening using Myriad’s prenatal cell-free DNA screen, Prequel. Myriad Genetics is a leader in genetic testing and precision medicine. The study was published in Prenatal Diagnosis.
Barchart · 04/16 08:15
BUZZ-U.S. STOCKS ON THE MOVE-Snap One, Encore Wire, Centene
The Dow Jones Industrial Average was down 0.45% on Monday. Goldman Sachs boosted by robust gains. Snap One, Encore Wire, Centene were among the top stocks on the NYSE. The S&P 500 and Nasdaq Composite both fell on the day. U.S. Retail sales were stronger than expected.
Reuters · 04/15 17:48
BUZZ-U.S. STOCKS ON THE MOVE-Cisco Systems, Inspired Entertainment, Spirit Airlines
Dow Jones Industrial Average was up 0.36% at 38,119.77. Goldman Sachs boosted by robust gains. Top three S&P 500 percentage gainers: M&T Bank, Centene, Snap One. Apple down 0.6% after falling in premarket trading.
Reuters · 04/15 16:13
Weekly Report: what happened at MYGN last week (0408-0412)?
Weekly Report · 04/15 09:10
Myriad Genetics (MYGN) Announces Favorable Research Results
NASDAQ · 04/11 14:00
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
NASDAQ · 04/09 13:10
MYRIAD GENETICS RESEARCH SHOWS REDUCTION IN HOSPITALIZATIONS FOR PATIENTS WITH DEPRESSION AFTER GENESIGHT TESTING
Reuters · 04/09 12:01
Weekly Report: what happened at MYGN last week (0401-0405)?
Weekly Report · 04/08 09:11
Weekly Report: what happened at MYGN last week (0325-0329)?
Weekly Report · 04/01 09:11
Why Is Myriad (MYGN) Down 1% Since Last Earnings Report?
NASDAQ · 03/28 15:30
Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?
Myriad Genetics, Inc. (NASDAQ:MYGN) has US$38.5m in debt. The company lost US$263m in the last year, but managed to grow its revenue by 11%. Myriad Genetics has more cash than debt, and has a healthy balance sheet. We look at the debt levels of the company to see if it is risky. We've identified 1 warning sign with myriad Genetics.
Simply Wall St · 03/28 10:09
Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay
NASDAQ · 03/27 11:51
Weekly Report: what happened at MYGN last week (0318-0322)?
Weekly Report · 03/25 09:11
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Myriad Genetics, Inc. Issued a patent that will strengthen its ability to deliver a tumor-informed, molecular residual disease assay to market. The company is a leader in genetic testing and precision medicine. The U.S. Patent and Trademark Office has issued the patent.
Barchart · 03/21 20:40
Myriad Genetics Says US Patent And Trademark Office Has Granted Patent That Covers Use Of Push-Button Blood Collection Devices For PCR-Based Fetal Sex Determination
Benzinga · 03/20 20:08
More
Webull provides a variety of real-time MYGN stock news. You can receive the latest news about Myriad Genetics through multiple platforms. This information may help you make smarter investment decisions.
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.